journal
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

journal
https://www.readbyqxmd.com/read/27856666/corrigendum
#1
(no author information available yet)
No abstract text is available yet for this article.
November 16, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27852792/fgfr-tacc-gene-fusions-in-human-glioma
#2
REVIEW
Anna Lasorella, Marc Sanson, Antonio Iavarone
Chromosomal translocations joining in-frame members of the fibroblast growth factor receptor-transforming acidic coiled-coil gene families (the FGFR-TACC gene fusions) were first discovered in human glioblastoma multiforme (GBM) and later in many other cancer types. Here, we review this rapidly expanding field of research and discuss the unique biological and clinical features conferred to isocitrate dehydrogenase wild-type glioma cells by FGFR-TACC fusions. FGFR-TACC fusions generate powerful oncogenes that combine growth-promoting effects with aneuploidy through the activation of as yet unclear intracellular signaling mechanisms...
November 16, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27852791/how-bad-are-your-seizures-and-did-the-treatment-help
#3
EDITORIAL
Robin Grant
No abstract text is available yet for this article.
November 16, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27838647/liquoral-liquid-biopsy-in-neoplastic-meningitis-enables-molecular-diagnosis-and-mutation-tracking-a-proof-of-concept
#4
LETTER
Caterina Marchiò, Sara Mariani, Luca Bertero, Cristiana Di Bello, Paola Francia Di Celle, Mauro Papotti, Roberta Rudà, Riccardo Soffietti, Paola Cassoni
No abstract text is available yet for this article.
November 11, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27765835/immune-modulatory-nanoparticle-therapeutics-for-intracerebral-glioma
#5
Nasser K Yaghi, Jun Wei, Yuuri Hashimoto, Ling-Yuan Kong, Konrad Gabrusiewicz, Edjah K Nduom, Xiaoyang Ling, Neal Huang, Shouhao Zhou, Brittany C Parker Kerrigan, Jonathan M Levine, Virginia R Fajt, Gwendolyn Levine, Brian F Porter, Eric G Marcusson, Kiyoshi Tachikawa, Padmanabh Chivukula, David C Webb, Joseph E Payne, Amy B Heimberger
BACKGROUND: Previously we showed therapeutic efficacy of unprotected miR-124 in preclinical murine models of glioblastoma, including in heterogeneous genetically engineered murine models by exploiting the immune system and thereby negating the need for direct tumor delivery. Although these data were promising, to implement clinical trials, we required a scalable formulation that afforded protection against circulatory RNases. METHODS: We devised lipid nanoparticles that encapsulate and protect the miRs from degradation and provide enhanced delivery into the immune cell compartment and tested in vivo antitumor effects...
October 8, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27688263/integrating-molecular-markers-into-the-world-health-organization-classification-of-cns-tumors-a-survey-of-the-neuro-oncology-community
#6
Kenneth Aldape, Romina Nejad, David N Louis, Gelareh Zadeh
BACKGROUND: Molecular markers provide important biological and clinical information related to the classification of brain tumors, and the integration of relevant molecular parameters into brain tumor classification systems has been a widely discussed topic in neuro-oncology over the past decade. With recent advances in the development of clinically relevant molecular signatures and the 2016 World Health Organization (WHO) update, the views of the neuro-oncology community on such changes would be informative for implementing this process...
September 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27683733/pediatric-low-grade-gliomas-implications-of-the-biologic-era
#7
Roger J Packer, Stephan Pfister, Eric Bouffet, Robert Avery, Pratiti Bandopadhayay, Miriam Bornhorst, Daniel C Bowers, David Ellison, Jason Fangusaro, Nicholas Foreman, Maryam Fouladi, Amar Gajjar, Daphne Haas-Kogan, Cynthia Hawkins, Cheng-Ying Ho, Eugene Hwang, Nada Jabado, Lindsay B Kilburn, Alvaro Lassaletta, Keith L Ligon, Maura Massimino, Schouten-van Meeteren, Sabine Mueller, Theo Nicolaides, Giorgio Perilongo, Uri Tabori, Gilbert Vezina, Katherine Warren, Olaf Witt, Yuan Zhu, David T Jones, Mark Kieran
For the past decade, it has been recognized that pediatric low-grade gliomas (LGGs) and glial-neuronal tumors carry distinct molecular alterations with resultant aberrant intracellular signaling in the Ras-mitogen-activated protein kinase pathway. The conclusions and recommendations of a consensus conference of how best to integrate the growing body of molecular genetic information into tumor classifications and, more importantly, for future treatment of pediatric LGGs are summarized here. There is uniform agreement that molecular characterization must be incorporated into classification and is increasingly critical for appropriate management...
September 28, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27663390/feasibility-phase-i-and-phase-ii-studies-of-tandutinib-an-oral-platelet-derived-growth-factor-receptor-%C3%AE-tyrosine-kinase-inhibitor-in-patients-with-recurrent-glioblastoma
#8
Tracy T Batchelor, Elizabeth R Gerstner, Xiaobu Ye, Serena Desideri, Daniel G Duda, David Peereboom, Glenn J Lesser, Sajeel Chowdhary, Patrick Y Wen, Stuart Grossman, Jeffrey G Supko
BACKGROUND: Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. METHODS: We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable inhibitor of type III receptor tyrosine kinases including PDGF receptor-β, Fms-like tyrosine kinase 3, and c-Kit in patients with recurrent glioblastoma. RESULTS: In an initial feasibility study, 6 patients underwent resection for recurrent glioblastoma after receiving tandutinib 500mg twice daily for 7 days...
September 23, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27663389/immunovirotherapy-with-measles-virus-strains-in-combination-with-anti-pd-1-antibody-blockade-enhances-antitumor-activity-in-glioblastoma-treatment
#9
Jayson Hardcastle, Lisa Mills, Courtney S Malo, Fang Jin, Cheyne Kurokawa, Hirosha Geekiyanage, Mark Schroeder, Jann Sarkaria, Aaron J Johnson, Evanthia Galanis
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor and has a dismal prognosis. Measles virus (MV) therapy of GBM is a promising strategy due to preclinical efficacy, excellent clinical safety, and its ability to evoke antitumor pro-inflammatory responses. We hypothesized that combining anti- programmed cell death protein 1 (anti-PD-1) blockade and MV therapy can overcome immunosuppression and enhance immune effector cell responses against GBM, thus improving therapeutic outcome...
September 23, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27663388/spinal-column-chordoma-prognostic-significance-of-clinical-variables-and-t-brachyury-gene-snp-rs2305089-for-local-recurrence-and-overall-survival
#10
Chetan Bettegowda, Stephen Yip, Sheng-Fu Larry Lo, Charles G Fisher, Stefano Boriani, Laurence D Rhines, Joanna Y Wang, Aron Lazary, Marco Gambarotti, Wei-Lien Wang, Alessandro Luzzati, Mark B Dekutoski, Mark H Bilsky, Dean Chou, Michael G Fehlings, Edward F McCarthy, Nasir A Quraishi, Jeremy J Reynolds, Daniel M Sciubba, Richard P Williams, Jean-Paul Wolinsky, Patricia L Zadnik, Ming Zhang, Niccole M Germscheid, Vasiliki Kalampoki, Peter Pal Varga, Ziya L Gokaslan
BACKGROUND: Chordomas are rare, locally aggressive bony tumors associated with poor outcomes. Recently, the single nucleotide polymorphism (SNP) rs2305089 in the T (brachyury) gene was strongly associated with sporadic chordoma development, but its clinical utility is undetermined. METHODS: In 333 patients with spinal chordomas, we identified prognostic factors for local recurrence-free survival (LRFS) and overall survival and assessed the prognostic significance of the rs2305089 SNP...
September 23, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27663387/an-independently-validated-nomogram-for-individualized-estimation-of-survival-among-patients-with-newly-diagnosed-glioblastoma-nrg-oncology-rtog-0525-and-0825
#11
Haley Gittleman, Daniel Lim, Michael W Kattan, Arnab Chakravarti, Mark R Gilbert, Andrew B Lassman, Simon S Lo, Mitchell Machtay, Andrew E Sloan, Erik P Sulman, Devin Tian, Michael A Vogelbaum, Tony J C Wang, Marta Penas-Prado, Emad Youssef, Deborah T Blumenthal, Peixin Zhang, Minesh P Mehta, Jill S Barnholtz-Sloan
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram to estimate individualized survival probabilities for patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. METHODS: This analysis included information on 799 (RTOG 0525) and 555 (RTOG 0825) eligible and randomized patients with newly diagnosed GBM and contained the following variables: age at diagnosis, race, gender, Karnofsky performance status (KPS), extent of resection, O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status, and survival (in months)...
September 23, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27655656/incidence-of-pseudoprogression-in-low-grade-gliomas-treated-with-radiotherapy
#12
Sophie E van West, Hein G de Bruin, Bart van de Langerijt, Annemarie T Swaak-Kragten, Martin J van den Bent, Walter Taal
BACKGROUND: As the incidence of pseudo-progressive disease (psPD), or pseudoprogression, in low-grade glioma (LGG) is unknown, we retrospectively investigated this phenomenon in a cohort of LGG patients given radiotherapy (RT). METHODS: All MRI scans and clinical data from patients with histologically proven LGG treated with radiation between 2000 and 2011 were reviewed. PsPD was scored when a new enhancing lesion occurred after RT and subsequently disappeared or remained stable for at least a year without therapy, including dexamethasone...
September 21, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27651472/seizure-control-as-a-new-metric-in-assessing-efficacy-of-tumor-treatment-in-low-grade-glioma-trials
#13
Edward K Avila, Marc Chamberlain, David Schiff, Jaap C Reijneveld, Terri S Armstrong, Roberta Ruda, Patrick Y Wen, Michael Weller, Johan A F Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R MacDonald, Ryo Nishikawa, Aashit Shah, Charles J Vecht, Paula Warren, Martin J van den Bent, Lisa M DeAngelis
Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy...
September 20, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27634933/radiation-injury-versus-malignancy-after-stereotactic-radiosurgery-for-brain-metastases-impact-of-time-dependent-changes-in-lesion-morphology-on-mri
#14
Sabine Wagner, Heinrich Lanfermann, Gerrit Eichner, Hubert Gufler
BACKGROUND: We sought to determine whether radiation-induced injuries could be distinguished from malignancy after stereotactic radiosurgery (SRS) by analyzing time-dependent changes in lesion morphology on sequential MRI for up to 55min. METHODS: In 31 consecutive patients treated with SRS for brain metastases, the time-dependent changes in lesion morphology were analyzed on MRI 2min, 15min, and 55min after contrast administration and on subtraction images. A simultaneous, matched-pairs approach was used for quantitative region of interest analysis of the area of the lesion...
September 15, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27630272/targeting-tyrosine-receptor-kinase-b-in-gliomas
#15
Kelly V Pinheiro, Camila Alves, Marienela Buendia, Mirela S Gil, Amanda Thomaz, Gilberto Schwartsmann, Caroline Brunetto de Farias, Rafael Roesler
No abstract text is available yet for this article.
September 14, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27880649/corrigendum
#16
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27880648/contents_page
#17
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27880647/subscriptions
#18
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27880646/editorial_board
#19
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27880645/cover
#20
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Neuro-oncology
journal
journal
34661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"